Cynosure Inc (CYNO) 53.51 $CYNO
Illumina (ILMN) Beats Q2 Earnings, Revenues; EPS View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:12PM CDT
Illumina (ILMN) ended the second quarter on an outstanding note, with both the top and bottom line results comfortably beating the Zacks Consensus Estimate.
ABMD: 119.50 (+1.53), MASI: 52.93 (-0.04), CYNO: 53.51 (-1.45), ILMN: 170.65 (+4.30)
Edwards Lifesciences (EW) Tops Q2 Earnings, '16 View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 11:39AM CDT
Edwards Lifesciences (EW) ended the second quarter on an encouraging note, with its financial numbers squarely beating the Zacks Consensus Estimate.
ABMD: 119.50 (+1.53), MASI: 52.93 (-0.04), CYNO: 53.51 (-1.45), EW: 114.23 (-0.29)
Cynosure, Inc. (Nasdaq: CYNO) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Tue Jul 26, 9:00AM CDT
What:
CYNO: 53.51 (-1.45), NDAQ: 71.42 (+0.66)
Cynosure Reports Net Income of $6.3 Million on Record Sales of $110.3 Million for the Second Quarter of 2016
PR Newswire - Tue Jul 26, 7:00AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today reported second-quarter 2016 net income of $6.3 million, or $0.27 per diluted share, an increase of 18.3 percent compared with $5.4 million, or $0.24 per diluted share, for the same period of 2015. On a non-GAAP basis, excluding non-cash unrealized foreign exchange measurement gains and losses and amortization of intangibles, second-quarter net income was $8.6 million, or $0.36 per diluted share, compared with $6.7 million, or $0.30 per diluted share, for the prior-year period. Revenue for the three months ended June 30, 2016 increased 32 percent to a record $110.3 million, compared with $83.7 million in the second quarter of 2015.
CYNO: 53.51 (-1.45)
Cynosure Receives Approval to Market SculpSure® in South Korea
PR Newswire - Tue Jul 26, 6:55AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today announced that it has received approval from the Korean Ministry of Food and Drug Safety (MFDS) to market SculpSure® for non-invasive lipolysis of the abdomen and flanks. The product will be marketed through the Company's direct sales force in Korea beginning in the third quarter of 2016.
CYNO: 53.51 (-1.45)
Med-Instrument Stocks to Post Earnings: EW, CYNO, GMED
Zacks Equity Research - Zacks Investment Research - Mon Jul 25, 9:59AM CDT
Medical is expected to reverse the trend with ease as earnings are expected to grow 1.8% driven by impressive top-line growth of 7.7% for the quarter.
CYNO: 53.51 (-1.45), GMED: 23.49 (+0.54), EW: 114.23 (-0.29)
Cynosure To Host Second-Quarter 2016 Financial Results Conference Call On July 26
PR Newswire - Thu Jul 14, 7:30AM CDT
Cynosure, Inc. (NASDAQ: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today announced that the Company will release its second-quarter 2016 financial results before the market opens on Tuesday, July 26, 2016 and host a conference call for investors and analysts that day at 9:00 a.m. ET.
CYNO: 53.51 (-1.45)
SmarTrend Watching for Potential Rebound in Shares of Cynosure After 1.87% Loss
Comtex SmarTrend(R) - Wed Jul 13, 3:30PM CDT
Cynosure (NASDAQ:CYNO) traded in a range yesterday that spanned from a low of $51.05 to a high of $52.51. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $51.10 on volume of 61,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CYNO: 53.51 (-1.45)
Cynosure to Ring NASDAQ Stock Market Closing Bell to Celebrate 25 Year Anniversary
PR Newswire - Thu Jun 16, 7:30AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today announced that President and CEO Michael Davin, along with other members of the Company's management team, will ring the Closing Bell at the NASDAQ Stock Market on Wednesday, July 27, 2016 to celebrate its 25th anniversary. Cynosure was founded by the late Horace Furumoto, PhD, a pioneer in the field of aesthetic medicine.
CYNO: 53.51 (-1.45)
SmarTrend Watching for Potential Pullback in Shares of Cynosure After 4.23% Gain
Comtex SmarTrend(R) - Wed Jun 01, 4:25PM CDT
Cynosure (NASDAQ:CYNO) traded in a range yesterday that spanned from a low of $47.93 to a high of $50.24. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $48.99 on volume of 385,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CYNO: 53.51 (-1.45)
Cynosure (CYNO) Up on FDA Approval for New 1064nm LDS
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:44AM CDT
Cynosure Inc. (CYNO) recently announced the receipt of FDA approval for marketing a new Laser Delivery System (LDS) for PicoSure.
IRMD: 19.08 (-0.28), MASI: 52.93 (-0.04), CYNO: 53.51 (-1.45), EXAC: 27.20 (+0.17)
Cynosure Announces Planned Retirement of Timothy W. Baker as President, Chief Financial Officer and Chief Operating Officer
PR Newswire - Wed May 25, 7:30AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today announced that Timothy W. Baker has notified the Company that he plans to retire to pursue philanthropic interests. Mr. Baker has served as Cynosure's President since 2014, as Chief Operating Officer since 2013, and as Chief Financial Officer since 2004. The Company has initiated a search for a CFO, and Mr. Baker plans to remain with Cynosure through the succession to help achieve a smooth transition. Michael R. Davin, the Company's Chairman and Chief Executive Officer, has been appointed President effective today.
CYNO: 53.51 (-1.45)
Cynosure Receives FDA Clearance to Market New PicoSure® Energy Delivery System for Tattoos and Pigmented Lesions
PR Newswire - Tue May 24, 7:30AM CDT
Broadening its product platform for tattoo removal and skin revitalization, Cynosure, Inc. (NASDAQ: CYNO) today announced that it has received U.S. Food and Drug Administration 510(k) clearance to market a new Laser Delivery System for PicoSure®, the world's first aesthetic picosecond laser. Together with the FDA cleared 532 nm and 755 nm wavelengths, Cynosure's new 1064 nm Laser Delivery System improves the multi-wavelength laser technology for removing the full color spectrum of tattoo inks in fewer treatments.
CYNO: 53.51 (-1.45)
SmarTrend Watching for Potential Pullback in Shares of Cynosure After 6.74% Gain
Comtex SmarTrend(R) - Tue Apr 26, 4:12PM CDT
Cynosure (NASDAQ:CYNO) traded in a range yesterday that spanned from a low of $47.11 to a high of $50.75. Yesterday, the shares gained 6.7%, which took the trading range above the 3-day high of $46.28 on volume of 867,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CYNO: 53.51 (-1.45)
Cynosure tops Street 1Q forecasts
Automated Insights - Tue Apr 26, 7:28AM CDT
WESTFORD, Mass. (AP) _ Cynosure Inc. (CYNO) on Tuesday reported first-quarter net income of $2.8 million, after reporting a loss in the same period a year earlier.
CYNO: 53.51 (-1.45)
Cynosure To Host First-Quarter 2016 Financial Results Conference Call On April 26
PR Newswire - Mon Apr 18, 7:30AM CDT
Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today announced that the Company will release its first-quarter 2016 financial results before the market opens on Tuesday, April 26, 2016 and host a conference call for investors and analysts that day at 9:00 a.m. ET.
CYNO: 53.51 (-1.45)
Cynosure Announces 20 Scientific Presentations at the American Society for Laser Medicine & Surgery's 36th Annual Conference
PR Newswire - Thu Mar 31, 7:30AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today announced that 17 scientific abstracts and three ePosters have been accepted for presentation at the 36th Annual Conference of the American Society for Laser Medicine & Surgery (ASLMS). The event is taking place today through April 3, 2016 at the Sheraton Boston Hotel & Hynes Convention Center in Boston, Massachusetts.
CYNO: 53.51 (-1.45)
Shares of CYNO Up 13.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Mar 08, 10:22AM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on February 18th, 2016 at $37.91. In approximately 3 weeks, Cynosure has returned 13.45% as of today's recent price of $43.01.
CYNO: 53.51 (-1.45)
Cynosure (CYNO) Up on Q4 Earnings and Revenue Beat
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 10:10AM CST
Shares of Cynosure (CYNO) rallied 4.2% ($1.43) to close at $35.20 on Feb 9, following the company's impressive fourth-quarter 2015 results.
ABMD: 119.50 (+1.53), CYNO: 53.51 (-1.45), EXAC: 27.20 (+0.17), LMNX: 21.86 (+0.43)
Cynosure beats Street 4Q forecasts
Automated Insights - Tue Feb 09, 7:21AM CST
WESTFORD, Mass. (AP) _ Cynosure Inc. (CYNO) on Tuesday reported fourth-quarter earnings of $7.2 million.
CYNO: 53.51 (-1.45)
Illumina (ILMN) Beats Q2 Earnings, Revenues; EPS View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 2:12PM CDT
Illumina (ILMN) ended the second quarter on an outstanding note, with both the top and bottom line results comfortably beating the Zacks Consensus Estimate.
ABMD: 119.50 (+1.53), MASI: 52.93 (-0.04), CYNO: 53.51 (-1.45), ILMN: 170.65 (+4.30)
Edwards Lifesciences (EW) Tops Q2 Earnings, '16 View Up
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 11:39AM CDT
Edwards Lifesciences (EW) ended the second quarter on an encouraging note, with its financial numbers squarely beating the Zacks Consensus Estimate.
ABMD: 119.50 (+1.53), MASI: 52.93 (-0.04), CYNO: 53.51 (-1.45), EW: 114.23 (-0.29)
Cynosure, Inc. (Nasdaq: CYNO) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Tue Jul 26, 9:00AM CDT
What:
CYNO: 53.51 (-1.45), NDAQ: 71.42 (+0.66)
Cynosure Reports Net Income of $6.3 Million on Record Sales of $110.3 Million for the Second Quarter of 2016
PR Newswire - Tue Jul 26, 7:00AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today reported second-quarter 2016 net income of $6.3 million, or $0.27 per diluted share, an increase of 18.3 percent compared with $5.4 million, or $0.24 per diluted share, for the same period of 2015. On a non-GAAP basis, excluding non-cash unrealized foreign exchange measurement gains and losses and amortization of intangibles, second-quarter net income was $8.6 million, or $0.36 per diluted share, compared with $6.7 million, or $0.30 per diluted share, for the prior-year period. Revenue for the three months ended June 30, 2016 increased 32 percent to a record $110.3 million, compared with $83.7 million in the second quarter of 2015.
CYNO: 53.51 (-1.45)
Cynosure Receives Approval to Market SculpSure® in South Korea
PR Newswire - Tue Jul 26, 6:55AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today announced that it has received approval from the Korean Ministry of Food and Drug Safety (MFDS) to market SculpSure® for non-invasive lipolysis of the abdomen and flanks. The product will be marketed through the Company's direct sales force in Korea beginning in the third quarter of 2016.
CYNO: 53.51 (-1.45)
Med-Instrument Stocks to Post Earnings: EW, CYNO, GMED
Zacks Equity Research - Zacks Investment Research - Mon Jul 25, 9:59AM CDT
Medical is expected to reverse the trend with ease as earnings are expected to grow 1.8% driven by impressive top-line growth of 7.7% for the quarter.
CYNO: 53.51 (-1.45), GMED: 23.49 (+0.54), EW: 114.23 (-0.29)
Cynosure To Host Second-Quarter 2016 Financial Results Conference Call On July 26
PR Newswire - Thu Jul 14, 7:30AM CDT
Cynosure, Inc. (NASDAQ: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today announced that the Company will release its second-quarter 2016 financial results before the market opens on Tuesday, July 26, 2016 and host a conference call for investors and analysts that day at 9:00 a.m. ET.
CYNO: 53.51 (-1.45)
SmarTrend Watching for Potential Rebound in Shares of Cynosure After 1.87% Loss
Comtex SmarTrend(R) - Wed Jul 13, 3:30PM CDT
Cynosure (NASDAQ:CYNO) traded in a range yesterday that spanned from a low of $51.05 to a high of $52.51. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $51.10 on volume of 61,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CYNO: 53.51 (-1.45)
Cynosure to Ring NASDAQ Stock Market Closing Bell to Celebrate 25 Year Anniversary
PR Newswire - Thu Jun 16, 7:30AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today announced that President and CEO Michael Davin, along with other members of the Company's management team, will ring the Closing Bell at the NASDAQ Stock Market on Wednesday, July 27, 2016 to celebrate its 25th anniversary. Cynosure was founded by the late Horace Furumoto, PhD, a pioneer in the field of aesthetic medicine.
CYNO: 53.51 (-1.45)
SmarTrend Watching for Potential Pullback in Shares of Cynosure After 4.23% Gain
Comtex SmarTrend(R) - Wed Jun 01, 4:25PM CDT
Cynosure (NASDAQ:CYNO) traded in a range yesterday that spanned from a low of $47.93 to a high of $50.24. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $48.99 on volume of 385,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CYNO: 53.51 (-1.45)
Cynosure (CYNO) Up on FDA Approval for New 1064nm LDS
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:44AM CDT
Cynosure Inc. (CYNO) recently announced the receipt of FDA approval for marketing a new Laser Delivery System (LDS) for PicoSure.
IRMD: 19.08 (-0.28), MASI: 52.93 (-0.04), CYNO: 53.51 (-1.45), EXAC: 27.20 (+0.17)
Cynosure Announces Planned Retirement of Timothy W. Baker as President, Chief Financial Officer and Chief Operating Officer
PR Newswire - Wed May 25, 7:30AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today announced that Timothy W. Baker has notified the Company that he plans to retire to pursue philanthropic interests. Mr. Baker has served as Cynosure's President since 2014, as Chief Operating Officer since 2013, and as Chief Financial Officer since 2004. The Company has initiated a search for a CFO, and Mr. Baker plans to remain with Cynosure through the succession to help achieve a smooth transition. Michael R. Davin, the Company's Chairman and Chief Executive Officer, has been appointed President effective today.
CYNO: 53.51 (-1.45)
Cynosure Receives FDA Clearance to Market New PicoSure® Energy Delivery System for Tattoos and Pigmented Lesions
PR Newswire - Tue May 24, 7:30AM CDT
Broadening its product platform for tattoo removal and skin revitalization, Cynosure, Inc. (NASDAQ: CYNO) today announced that it has received U.S. Food and Drug Administration 510(k) clearance to market a new Laser Delivery System for PicoSure®, the world's first aesthetic picosecond laser. Together with the FDA cleared 532 nm and 755 nm wavelengths, Cynosure's new 1064 nm Laser Delivery System improves the multi-wavelength laser technology for removing the full color spectrum of tattoo inks in fewer treatments.
CYNO: 53.51 (-1.45)
SmarTrend Watching for Potential Pullback in Shares of Cynosure After 6.74% Gain
Comtex SmarTrend(R) - Tue Apr 26, 4:12PM CDT
Cynosure (NASDAQ:CYNO) traded in a range yesterday that spanned from a low of $47.11 to a high of $50.75. Yesterday, the shares gained 6.7%, which took the trading range above the 3-day high of $46.28 on volume of 867,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CYNO: 53.51 (-1.45)
Cynosure tops Street 1Q forecasts
Automated Insights - Tue Apr 26, 7:28AM CDT
WESTFORD, Mass. (AP) _ Cynosure Inc. (CYNO) on Tuesday reported first-quarter net income of $2.8 million, after reporting a loss in the same period a year earlier.
CYNO: 53.51 (-1.45)
Cynosure To Host First-Quarter 2016 Financial Results Conference Call On April 26
PR Newswire - Mon Apr 18, 7:30AM CDT
Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today announced that the Company will release its first-quarter 2016 financial results before the market opens on Tuesday, April 26, 2016 and host a conference call for investors and analysts that day at 9:00 a.m. ET.
CYNO: 53.51 (-1.45)
Cynosure Announces 20 Scientific Presentations at the American Society for Laser Medicine & Surgery's 36th Annual Conference
PR Newswire - Thu Mar 31, 7:30AM CDT
Cynosure, Inc. (NASDAQ: CYNO) today announced that 17 scientific abstracts and three ePosters have been accepted for presentation at the 36th Annual Conference of the American Society for Laser Medicine & Surgery (ASLMS). The event is taking place today through April 3, 2016 at the Sheraton Boston Hotel & Hynes Convention Center in Boston, Massachusetts.
CYNO: 53.51 (-1.45)
Shares of CYNO Up 13.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Mar 08, 10:22AM CST
SmarTrend identified an Uptrend for Cynosure (NASDAQ:CYNO) on February 18th, 2016 at $37.91. In approximately 3 weeks, Cynosure has returned 13.45% as of today's recent price of $43.01.
CYNO: 53.51 (-1.45)
Cynosure (CYNO) Up on Q4 Earnings and Revenue Beat
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 10:10AM CST
Shares of Cynosure (CYNO) rallied 4.2% ($1.43) to close at $35.20 on Feb 9, following the company's impressive fourth-quarter 2015 results.
ABMD: 119.50 (+1.53), CYNO: 53.51 (-1.45), EXAC: 27.20 (+0.17), LMNX: 21.86 (+0.43)
Cynosure beats Street 4Q forecasts
Automated Insights - Tue Feb 09, 7:21AM CST
WESTFORD, Mass. (AP) _ Cynosure Inc. (CYNO) on Tuesday reported fourth-quarter earnings of $7.2 million.
CYNO: 53.51 (-1.45)
